Corvus Pharmaceuticals
Clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer.
Launch date
Employees
Market cap
CAD435m
Enterprise valuation
CAD372m (Public information from Sep 2024)
Share price
$5.61 CRVS
Burlingame California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | 5.6m | 5.8m |
| % growth | - | - | - | - | - | - | 4 % |
| EBITDA | (43.8m) | (43.2m) | (32.6m) | (23.3m) | - | - | - |
| Profit | (6.0m) | (43.2m) | (41.3m) | (27.0m) | (24.7m) | (39.0m) | (50.1m) |
| % profit margin | - | - | - | - | - | (692 %) | (858 %) |
| EV / revenue | - | - | - | - | - | 49.7x | 48.0x |
| EV / EBITDA | -2.3x | -2.6x | -1.2x | -3.7x | - | - | - |
| R&D budget | 31.8m | 29.1m | 24.5m | 16.5m | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$33.5m | Series A | ||
| N/A | $75.0m | Series B | |
| N/A | N/A | IPO | |
* | $30.6m | Post IPO Equity | |
| Total Funding | CAD148m | ||
Related Content
Recent News about Corvus Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.